Verustat expands services
By HME News Staff
Updated 10:02 AM CST, Thu February 3, 2022
NASHVILLE, Tenn. – Verustat, which offers a full-service remote patient monitoring system, has expanded its services to provide multiple levels of support for decentralized clinical trials (DCT). Verustat's customizable SELECT DCT program is a streamlined solution that offers increased compliance, stability and accuracy in a single, customizable source, the company says. "The launch of Verustat's DCT platforms marks an important evolution in our pursuit to modernize the way clinical trials are conducted for the life science industry," said Andy Maloy, senior vice president of technology and clinical trials at Verustat. "We are excited to have built this custom solution that services numerous DCT needs and will improve the overall experience for all parties." Verustat designed the DCT program to enhance the patient experience and improve compliance at their home, with each DCT customizable to their requirements. Service offerings include Verustat’s RPM platform, telemedicine visits, medical peripheral hardware sourcing, multiple communication methods, global customs management, Tier 2 technical support and equipment leasing. Verustat's trained call center team ensures that patients receive full training in how to use their medical and mobile devices. They are also available to answer any questions and to help ensure compliance during the trial.
Comments